Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | KMO | O15229 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627186 | 1.00 | NPC1 (0.69) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL12170961 | 0.88 | NPC1 (0.58) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL29627363 | 0.88 | KDM4E (0.56) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL1845567 | 0.88 | KDM4E (0.56) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL5341764 | 0.87 | DYRK1A (0.52) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL28753178 | 0.83 | ERN1 (0.52) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL29627194 | 0.83 | ERN1 (0.52) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL192332 | 0.82 | NPC1 (1.00) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| Hydrochloric Acid SCHEMBL4255724 | 0.81 | NPC1 (0.96) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL10347638 | 0.81 | NPC1 (0.96) | NPC1RAB9AKDM4ETDP1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20220348560-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2022-11-03 | — | — | US | disclosed |
| EP-4038062-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | Kainos Medicine, Inc. (KR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114466844-A | N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient | 康佳诺医疗科技发展有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2021066559-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021066559-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2021-04-08 | — | — | WO | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348560-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | IRAK4, IRAK1, IRAK2 | NPC1 1224/4885RAB9A 2926/4885KDM4E 101/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | NPC1 880/4885RAB9A 2924/4885KDM4E 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.